

# **FIBROBIOLOGICS, INC.**

**Reported by**  
**GARCIA RUBEN A**

## **FORM 4** (Statement of Changes in Beneficial Ownership)

**Filed 12/12/25 for the Period Ending 12/11/25**

Address     455 E. MEDICAL CENTER BLVD  
                  SUITE 300  
                  HOUSTON, TX, 77598

Telephone    281-671-5150

                  CIK    0001958777

Symbol        FBLG

SIC Code      2834 - Pharmaceutical Preparations

Industry      Biotechnology & Medical Research

Sector         Healthcare

Fiscal Year    12/31

# FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

OMB APPROVAL  
OMB Number: 3235-0287  
Estimated average burden hours per response... 0.5

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> <b>GARCIA RUBEN A</b> (Last) (First) (Middle) <b>C/O FIBROBIOLOGICS, INC., 455 E. MEDICAL CENTER BLVD., SUITE 300</b> (Street) <b>HOUSTON, TX 77598</b> (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol <b>FibroBiologics, Inc. [ FBLG ]</b>					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) <b>General Counsel</b>				
			3. Date of Earliest Transaction (MM/DD/YYYY) <b>12/11/2025</b>									
			4. If Amendment, Date Original Filed (MM/DD/YYYY)					6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person				

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Trans. Date 12/11/2025	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)					6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	Amount	(A) or (D)	Price					
Common Stock				P		<b>140,000</b>	<b>A</b>	<b>\$0.34 (1)</b>				<b>140,000</b>	<b>D</b>

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Securities (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	

#### Explanation of Responses:

(1) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from \$0.3333 to \$0.3504 on December 11, 2025. The reporting person will provide upon request to the SEC, the Issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

#### Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
<b>GARCIA RUBEN A</b> <b>C/O FIBROBIOLOGICS, INC.</b> <b>455 E. MEDICAL CENTER BLVD., SUITE 300</b> <b>HOUSTON, TX 77598</b>			<b>General Counsel</b>	

#### Signatures

**/s/ Ruben A. Garcia**

**12/12/2025**

**\*\***Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.